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(9.51.0); standing (8.41.8); sleep (7.92.3); work-related activities (7.92.4); walk-
ing (7.82.2); sexual activity (7.71.7); emotions (7.72.4); lifting (7.62.5); sitting
(7.52.0); social activities (7.22.4); and traveling (6.82.2). CONCLUSIONS: Quali-
tative interviews identified a wide-variety of bothersome symptoms and impacts
experienced by patients with cLBP. Patient-reported outcome instruments should
measure those experiences, which reflect concepts most relevant to patients. Ad-
ditional work is needed to assess whether items measuring these concepts are
sensitive to change with treatment.
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OBJECTIVES: The primary objective was to examine the effect of 8% capsaicin
patch on change in “usual pain” using a PNRS (Pain Numeric Rating Scale) from
baseline to end of treatment. A secondary objective was to examine utility scores
assessed by the EQ-5D. METHODS: Adult patients (n211) diagnosed with periph-
eral neuropathic pain (excluding diabetes polyneuropathy) were included. The fol-
lowing parameters were investigated over a 12 week follow up period after a single
application: - Pain Numeric Rating Scale (PNRS, 0-10) to assess average pain inten-
sity over the last 24 hours, i.e., “usual pain” - EQ-5D - Size of treated area. RESULTS:
A total of 196 patients completed the study, 66% women and 34% men. Mean age
was 54.2 years (range 18-87). At baseline, the “usual pain” intensity was 6.3 (SD 1.8).
The mean change of PNRS from baseline to 14 - 90 days post treatment (average
pain reduction) was -0.90 (SD 2.08), p  0.001. Maximum mean reduction of “usual
pain” at any time point was -1.77 (SD 2.36), p 0.001. Mean EQ-5D health score was
0.29 (SD 0.31) at baseline (range -0.38-1.00). During the post-treatment period the
change was 0.26 (SD 0.30), p  0.001. At baseline, 66% of all patients reported
“Extreme Problem” in the pain/discomfort dimension and corresponding figures
for the post-treatment period was 43%. Median area treated was estimated to 179
cm2(range 3-1120) corresponding to 1.3 patches used per patient per treatment.
CONCLUSIONS: In this population of patients with peripheral neuropathic pain
and a markedly reduced QoL, a single treatment of capsaicin 8% significantly re-
duced patients’ experience of “usual pain” and improved short-term QoL evaluated
by EQ-5D.
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OBJECTIVES: Review the development and properties of PRO instruments used in
clinical trials and observational studies of patients with SLE. METHODS: A struc-
tured search was conducted to identify published articles in 2005-2011 through key
literature databases (EMBASE and MEDLINE/PUBMED). Conference abstracts from
targeted rheumatology, outcomes research and quality-of-life (QOL) scientific
meetings in 2009-2011 were included. SLE therapy clinical trials within the past five
years were identified through the ClinicalTrials.gov database. RESULTS: Over 60
different PRO instruments were used in SLE-related research; 7 were lupus specific,
11 assessed general QoL and the rest assessed select (diverse) disease symptoms
(e.g., fatigue, pain) or other patient attributes (e.g., satisfaction, adherence). The
SF-36, LupusQoL, and LupusPRO were most frequently used in SLE research. These
instruments have 36, 34, and 43 items, respectively. All three instruments have a
recall period of past four weeks; they demonstrated robust reliability and construct
validity when used in SLE patient samples, but generally weak associations
(r0.12-0.29) with SLE disease-activity indices. Validated symptom-specific FACIT-
Fatigue scale was also used in some studies to measure this important aspect of
patient experience and it correlated with SLE disease-activity indices. Recently, 10
items from the LupusPRO were validated for use as ‘Lupus Impact Tracker’ (LIT) to
retain the reliability and validity of the longer tool while decreasing questionnaire
burden. Brief validated instruments used in rheumatic-diseases (e.g., RAPID3: 15
items) are also being studied in SLE. CONCLUSIONS: The SF-36, LupusQoL, and
LupusPRO are the most widely used validated PRO instruments, but these have a
varying degree of questionnaire burden and specificity to SLE symptoms. Shorter
versions of validated PROs (e.g., SF-12, LIT) or instruments such as RAPID3 may
minimize questionnaire burden. The practicality of these PRO instruments for use
in daily practice to discriminate clinically meaningful changes in patient-reported
SLE treatment outcomes deserves further investigation.
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OBJECTIVES: To identify symptoms and impacts associated with chronic low back
pain (cLBP) that patients report spontaneously and in response to probes during
concept elicitation interviews.METHODS:Adult patients (18-80 years) with clinical
diagnosis of cLBP of non-malignant origin present for at least 3 months with a
current pain score 4 on a 0-10 numerical rating scale (NRS) were recruited from
U.S. and Germany sites. In order to explore relevance of concepts to patients,
trained qualitative interviewers conducted semi-structured individual interviews,
using open-ended questions to elicit spontaneous reports of symptom/impact con-
cepts, followed by probe questions to assure full coverage of concept domains.
Transcripts were coded using Atlas.ti and summarized by distinct concepts. Inter-
view guide notations were used to tag each concept offered by spontaneous versus
probed report. RESULTS: Forty-three patient interviews were conducted (mean
age: 48.613.0, 53.5% female, 74.4% -White/Caucasian). Mean (SD) pain NRS score
was 6.7(1.3). Spontaneously reported symptoms included: Numbness (51.2% of sub-
jects), Burning (39.5%), and Pain that was Shooting (37.2%), Stabbing (37.2%), and
Sharp (37.2%). The low back pain symptoms reported most often in response to
probes included Stiffness (55.8% of subjects), Excruciating Pain (41.9%), Pressure
(39.5%), Cramping (32.6%), and Pins and Needles (30.2%). Spontaneously reported
impacts included interference with: Walking (65.1%), Sitting (62.8%), Exercise
(58.1%), Leisure Activities (58.1%), Sleeping (55.8%), Household Chores (53.5%), and
Emotional Impacts (48.8%). Impacts reported most often in response to probes
included Low Energy because of pain (67.4%), Productivity (65.1%), Financial Impact
(46.5%), Driving (39.5%), and Relationships (37.2%). CONCLUSIONS: Given the vari-
ety of symptoms and impacts described by patients as part of their cLBP experi-
ence, those reported spontaneously may be more relevant to patients compared to
those reported upon probes. Characterizing patient reported concepts by sponta-
neous and probed may be useful in increasing the overall sensitivity of the patient
reported outcome assessment tool to detect change.
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OBJECTIVES: Evaluate the reliability and validity of the LIT, a 10-item PRO assess-
ment of the impact of SLE on the patient’s life. Additionally, the acceptability and
feasibility of LIT from the patient’s and physician’s perspectives was assessed.
METHODS: Baseline data were collected on 325 SLE patients during a clinic visit.
Patients completed the LIT, SF-36v2, LupusQoL, and PHQ-9. Both patients and phy-
sicians completed a questionnaire on the feasibility/acceptability of LIT. Patients
completed the LIT 7-14 days following baseline to assess test-retest reliability.
Physicians completed disease activity assessments (SELENA-SLEDAI, BILAG, and
SLICC/ACR Damage Index), a physician’s global assessment (PGA) and patient’s
recent flare status. Reliability was evaluated using internal consistency methods
(Cronbach’s alpha) and test-retest methods (intra-class correlation). Convergent
validity was evaluated by correlating LIT scores with scale scores from the SF-36v2,
LupusQoL, and PHQ-9. Construct validity was evaluated by comparing mean LIT
scores across patients that differed in PGA ratings and presence/absence of a recent
flare. ANOVA and Student’s t-tests were used to test mean differences in LIT scores
across patient groups. It was hypothesized that LIT scores would be lower among
patients with lower PGA ratings and no recent flare. RESULTS: Internal consistency
and test–retest reliabilities of LIT were 0.90 and 0.88, respectively. Convergent va-
lidity correlations ranged from -0.63 to -0.75 with SF-36v2 scales, from -0.42 to -0.75
with LupusQoL scales, and 0.75 with the PHQ-9. Mean LIT scores differed as hy-
pothesized across patients with different PGA ratings (F5.8, df2, p0.004). Mean
LIT scores differed between patients with and without a recent SLE Flare (t2.11,
p0.038). The majority (70%) of both patients and physicians found LIT to be
acceptable and feasible to administer in a clinic setting. CONCLUSIONS: The LIT is
a reliable and valid instrument for assessing the impact of SLE on patient’s func-
tioning and well-being.
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OBJECTIVES: Scarce data is available on the economic burden associated with
haemophilia B (HB). The aim of this study was to evaluate in a representative
French HB population the impact on health-related quality of life (HRQOL) and to
estimate the costs associated with its management. METHODS: EQOFIX is a pro-
spective cohort study in patients with moderate and severe HB with one year
follow-up. Data collected included: patients’ demographic and clinical character-
istics, severity status, therapeutical approach, FIX consumption and all other re-
sources used. Two types of HRQOL were used: generic (Kidscreen for children and
SF-36 for adults) and specific (QUAL-HEMO, specific to haemophilia patients). The
French national health insurance perspective was considered to estimate the av-
erage annual cost using official cost database. RESULTS:A total of 155 patients had
been included by 27 centres, representing a coverage rate of 25% of the French
global population suffering from severe and moderate HB: 104 adults (74 severe and
30 moderate) and 51 children (40 severe and 11 moderate). 30.4% of patients re-
A515V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
